| Title |
The economic pressures for biosimilar drug use in cancer medicine
|
|---|---|
| Published in |
Targeted Oncology, January 2012
|
| DOI | 10.1007/s11523-011-0196-3 |
| Pubmed ID | |
| Authors |
Paul Cornes |
| Abstract |
The main rationale for using biosimilar drugs is for cost saving. The market development for biosimilar drugs will therefore depend on the degree to which cost saving measures are required by nations, medical insurers and individuals and the absolute savings that could be gained by switching from original drugs. This paper is designed to discover the degree to which financial constraints will drive future health spending and to discover if legal or safety issues could impact on any trend. A structured literature search was performed for papers and documents to 27 August 2011. Where multiple sources of data were available on a topic, data from papers and reports by multinational or national bodies were used in preference to data from regions or individual hospitals. Almost all health systems face current significant cost pressures. The twin driver of increasing cancer prevalence as populations age and cancer medicine costs rising faster than inflation places oncology as the most significant single cost problem. For some countries, this is predicted to make medicine unaffordable within a decade. Most developed countries have planned to embrace biosimilar use as a cost-control measure. Biosimilar introduction into the EU has already forced prices down, both the price of biosimilar drugs and competitive price reductions in originator drugs. Compound annual growth rates of use have been predicted at 65.8% per year. Most developed countries have planned to embrace biosimilar use as a major cost-control measure. Only legal blocks and safety concerns are likely to act against this trend. For centralised healthcare systems, and those with a strong tradition of generic medicine use, biosimilar use will clearly rise with predictions of more than 80% of prescriptions of some biologic drugs within 1 year of market entry in the USA. Delaying the implementation of such programmes however risks a real crisis in healthcare delivery for many countries and hospitals that few can now afford. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 50% |
| Switzerland | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 1% |
| Brazil | 1 | 1% |
| United Kingdom | 1 | 1% |
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 85 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 19% |
| Student > Bachelor | 13 | 14% |
| Researcher | 12 | 13% |
| Student > Master | 12 | 13% |
| Other | 9 | 10% |
| Other | 13 | 14% |
| Unknown | 14 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 27% |
| Agricultural and Biological Sciences | 11 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
| Biochemistry, Genetics and Molecular Biology | 7 | 8% |
| Economics, Econometrics and Finance | 5 | 6% |
| Other | 21 | 23% |
| Unknown | 12 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2012.
All research outputs
#15,242,272
of 22,663,150 outputs
Outputs from Targeted Oncology
#265
of 546 outputs
Outputs of similar age
#162,851
of 245,783 outputs
Outputs of similar age from Targeted Oncology
#4
of 5 outputs
Altmetric has tracked 22,663,150 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 546 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 245,783 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.